KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Inventory (2018 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Inventory for 8 consecutive years, with $82.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 5.36% year-over-year to $82.7 million, compared with a TTM value of $82.7 million through Dec 2025, up 5.36%, and an annual FY2025 reading of $82.7 million, up 5.36% over the prior year.
  • Inventory was $82.7 million for Q4 2025 at Alnylam Pharmaceuticals, up from $75.4 million in the prior quarter.
  • Across five years, Inventory topped out at $131.9 million in Q1 2023 and bottomed at $65.6 million in Q1 2025.
  • Average Inventory over 5 years is $90.0 million, with a median of $85.4 million recorded in 2021.
  • Peak annual rise in Inventory hit 67.96% in 2023, while the deepest fall reached 30.87% in 2023.
  • Year by year, Inventory stood at $86.4 million in 2021, then skyrocketed by 49.33% to $129.0 million in 2022, then tumbled by 30.87% to $89.1 million in 2023, then dropped by 11.93% to $78.5 million in 2024, then grew by 5.36% to $82.7 million in 2025.
  • Business Quant data shows Inventory for ALNY at $82.7 million in Q4 2025, $75.4 million in Q3 2025, and $71.7 million in Q2 2025.